1、t:pII$*tP (csco) *mtq8i17Iii2022 GUIDELINES OF CHINESE SOCIETY OF CLINICAL ONCOLOGY CSCO lItiiHtP (csco) *XmRifiii 2022 GUI DELI NES OF CHINESE SOCIETY OF CLIN ICA L ONCOLOGY (CSCO) SOFT TISSUE SARCOMA ;1? l. Ii. iJ. t Jjt. Jt&pJf, fHE! lII:jH:E!l& (CIP) ?g5Jiii 9=OOIIfuJ*RjT:JOO (eseo) $Xli,R:JOOiT
2、fiJ . 2022 / 9=OOllfuanjT:JOOf,iJIfFff1g.t,R.-:jGJ? : .J.,:JlItf:.Jt&U, 2022.4 ISBN 978-7-117-32967-5 I. CD9= IT. CD9= ill . CDfJli,Rn E m IJ!ij * ill: ;m ( Ujliff;)(igt#-snJ ) $ iJj.Jj f nCf $ )i1J-J5* $ :E 11=1 :;r: t=l *IT M(fij T8f.l17- -1E ( Zhinan 2022 llOl f1fIm$ ( OS) QJR!lJIII lim lim lim .
3、!rTl Jrr .!rTl Iffi Iffi Iffi XJ-_ vu II , -= -;0;, , f-H I%1l*1mt -ff)4-dt -, .II m !ffi lffi r:14-B-t 1flt :ill jj 11 .LJ. -B-+t +t -B- -B 1m f E -B-f -B-ImIBll IBll f + +t!t!+ tl l * l )It * )+ lID + t! t! 1iu H j l l j l l * -B- -B- EJll)IJ mm )(j: Jll)IJ )(j: E Jll)IJ = mmmm -Emm l mm lJ mm t!
4、fffit! t! t! Ett mm:fr Wlltj j:3-mmmm mm St!:3-:3JJT )(j: i!i t! t! :B mm ,= = cfl -E-Et!mm mm t! -Bc, ) NtPgDm$tH?ttPg*TY t ! .LNY,s;!-Iijq,l?t IIYtPg?t;$t;$r:P . El El NY,s;!-Iijq,l?ttPg?t;$N;$r:P : , E3 V NtPgr:PliEi:fIr:P ElB$l :gB-! r:PtPggfgDm$?ttPg;$l fu NtPg?t23Y;$l I NtPgDm$?ttPg;$l 1TH N23
5、YVW . NEI3!W?t!*D$l . .L N-IM.g?t!*D$l 8 r:PtPg?tt:l:Htfl?t;$!;$fNr:P;t , tjj # t?t23Y-W&! :f;f;ti tHfg?ttPg?t;$N;$r:P jlj2ID ( Y1:HGt. .) (i1Gt.iHff!f:Eh1) a!lm * )Uw! p $im JJX; -4B5Bn* BBi ;t M ;t !lfi m J-lHim :=E . :=E;a :=E l LLr*Jt= jGrjlffilf4 tf*;jGmrjlffilf4 ,*AJJ5z:,t?,jGIln;&(P;f4 8 *j1*
6、 LIJ jG:g9f4 t*iFjGilJrjlffil9f4 tf*;jGrjlffilf4 ,*f4t*;1TjGi1tMDlljGf4 _bm/AjGrjlffilf4 ,*LIJ*j1-jGrjlffilf4 t*rjlffiljGffil&ffilf4 9) 11*iZjGWl-8*j1WpffiljG(P;1f4 ,*f4jGrjlffiljGrjlffilf4 * .AJsJJ5(*iZjGrjlffil(P;f4 -;licpfg:q:J/H4wNt:P 2 NtPDm$tP6D 82 NtP9:f!:$:223Yt:P . fD2 NIWIJjIW*J/t:P!SlWtPI
7、Tlt:P . 2 NlWtP!*Dt;1 ! 2 t:!lWtP!*Dt;1 W NlWtP!f)!fNt:P . wffi NlWtPi!*Dfg1 !?#b NlWtPl!MtPNt:P fu!:g?# N4I!MtP ( 1!=r ) m=.w:$:!:$:223Yt:P J/t:PlWtP-.w8t:l* ?f1 Nl!MtPlWtPNt:P IV:E UY2ITlt:PflE3 . ;Wr:E :j=:tl J*;1* IIJI M,)(i! * * ill $MOf,f.ffii: El:k:#jtCPLlJJfrjlffilf4 El:k:#MCPLlJJfrjlffil4 c
8、P :#f4:#JfrjlffilJfrjlffil4 cpA$rjlffilcp ;*:k*ft$1JJfrjlffil4 :l t:9:k*;j;Jfrjlffil4 :l t:9:f5=(*;Jfffi91f4 FF1IilE#iiHS, my:jifit-If6BJiJRtt, 0&9:*jlME#tf-JTili*, *UJ:E9=l 00*mrjlffilBiJTm fi:tl.l, 9=loollffiJ5trjlffil#fr (CSCO ) B*1*z-JlI$*, IlffiJ5tifiml.lB*UJ:EHmJfBrOJ ,0 PTifiim!BPJRtt, 1tt15T
9、*9=loo, :JRt8IZFittgr,BoofDt81Z 9=loo$iilD10 i1I), t8IZ)1HD#*/FS1jB*9=l00, CSCO :tl.lmy:jt8IZ*, F5fDifi- fBPJRiRrjliiifiBi1fr1J11ij=l1JrnJ J1t, CSCO :tl.lB*UJ:E, *Bj-ll lffiJ5tIDJJMlBifi0 mf:I$1IilE#im$fD;J:!:iRJi7f%im$J5U, I6JB1iS15t-If6BPJRifD5iJ:1J1tl:;px:li&o ilE :I$J5U_h PJRiHB1J, 1t) I mi; im$
10、J5U$F=J, ;J:!:iRJif1E;, 9XPJRti$B1J, 1t) II m:li; IlffiJ5t;l;ffl, 19im$J5U/FF=JB, 1t) III mio CSCO :tl.lToop;j?HlffiJ5tliJt pxfD CSCO m, liflilJ:E:lim, U1T*1llffiJ5t;l;i9=l1fffl o CSCO :Il.lI1tD1fr f1, Tim$, 1Ey:jPJR, iStS-mBml.l, :tS-ftooBllffiJ5t;l;jji a ft11Jm1U*NB&tm m, m:tl.l:JfB1iA, fRf&tS-Imh
11、)(, 1CSCO :tl.lBf4#ti, IEttfDB11Jio 11 EUR CSCO ifJWJiiHJi!iHl / 1 CSCO ifJWJmm / 2 CSCO xffit.HooifJmWJ 2022 :mJf, / 3 (-) I!l / gI&TxffiHOO / 5 1 itfJT!35Jnf.l 6 1.1 ;JiH=rWii# / 6 1.2 ElftWiif / 8 1.3 ittfJT / 12 1.4 BltIl / 16 2 (pgIlf& I 22 2.1 ;3l&nit / 22 2.2 WiilmitfJT*1II / 25 3 9f4;fi ( MS
12、TS/Enneking 9f45inf.l) I 30 3.1 9rf4illWIr-J5Es / 30 3.2 /FiEJBltIl9rf-l.;i:lfiffii:IJlU / 30 3.3 FiHUt)MtIr-J$:.El.tq9rWi:lfi / 38 4 1;fi I 49 4.1 *iWfi / 49 13 Elm 4.2 *Fo1:&17 / 52 1 0 i:1.JJ4.3 lzi!j,f,1:&17 / 53 10.1 Il.ii 5 1t;fjfi (AJCC BWl) / 58 10.2 Jfi: 5.1 *Wit17 / 58 (=) E$Xffi 5.2 *Foit
13、17 / 67 1 itttri.!355.3 m9.t(B/FPJtJjjit17 / 71 1.1 ;f,f,fj 6 reioJ /A5i;fjfi / 83 1.2 El?t 6.1 8JtIl9.t/FPJt)J$Xmtqjj(B=IoJ;g17 / 83 1.3 f 6.2 ?*WgI.illZl!l!.BJtEl9.t/FPJt)J$Xmjj(BIoJ;g17 / 86 1.4 BltF. 6.3 ?*WgI.illZl!l!.BJtIl9.t/FPJt)J$X.tqjj(B(sl:;g17 / 93 2 Wgff*m.illZB$XffitqjjP9f4;fjfi (n51)
14、/ 100I 7 2.1 ;i5f 8 ro4m;fjfif*:tiI1:ff / 109 2.2 Wgrn 8.1 .LtOi / 109 3 9f-l.;fj18.2 tp*(BrllJJfo;g17 / 114 4 1;fj18.3 J!J,f,Jl11i(Br9!1lJJ / 124 5 *f8.4 tl:lllD.1iJmIlJlG(Br9!1lJJ / 132 6 :& /$8.5 $Xmjj(sl:;g17ffi*(B1i;JjW / 138 7 f+t 9 f+t1.HF / 142 8 i:1.JJ / 14 10 .mJJ / 148 10.1 iiJJB1f8J1B 14
15、8 1 0.2 lliiJJIJ;n1B / 149 (=) JmJljJ$fflJHffli I 155 1 it!BW3 / 156 1 . 1 ;1iHTW9 / 156 1.2 l?tW9f / 157 1.3 iffJT!iSJi5 160 1.4 Blm / 161 2 fIf& / 162 2.1 ;i5&7Ji; / 162 2.2 W9WiffJT1B / 165 3 9if-I.;gi7 / 167 4 JJ1(t-f;gfi / 173 5 -#lttfi / 178 6 / $PJt) RPS tfi / 181 7 f-+tMF / 182 8 .mJJ / 184
16、15 EI (=) -:;Hm(pjj I 187 (g) f1 I 217 1 itWT-35:JM 188 f1 1 1 . 1 ;litfT(pg / 188 f1 2 $J 1.2 Elp!(pgf / 190 11 3 $J 1.3 JJ1ittfJT / 192 11 4 2 (pgI!f&* / 2.1 ;3f.nit / 194 194 11 5 f1 6 :fj :11 2.2 (pgIfittfJT / 196 f1 7 IH 3 )gftJj)ft / 3.1 xmlfHJJ 3.2 ?7f.:j.;gfi 199 200 202 11 8 /f 11 9 ;i 11 1
17、0 I 3.3 n9:M;gff 204 f1 11 : 3.4 *7t;gff 206 3.5 PJtnMJ*-FHjj(pg;gff / 211 3.6 /FPJtntJ*-Ffjj(pg;gff / 213 4 mi.JJ / 214 4.1 lHiJJB1i8 21 4 4 .2 lHiJJPg 214 16 () f1 / 217 f1 1 m 5 #R$xmJiOO WHO S ( 2020) fD ICD ifIiUI / 218 f1 2 $XElHiOOffi9I1m5B1t1&Z / 223 f1 3 $xEliOOS-Tt&i!jW / 225 1 4 rJf*9;D /
18、 233 f1 5 ;t(ml.iOO;f:H7W TNM IlffiJ5tSltm,Jiat / 234 f1 6 t;Y:HJl,iOOffm ( IRS) #JE -ffi9lSlt*m 235 11 7 Hl!ifD)j,Ri,m)(MiOOffl;&5Jg / 236 1 8 /fPJt)gX;$HUxmtqiOO8fD.J / eAi;gfiFJw.J 238 f1 9 mmSIE$xmiOO8;gfi1J51 (3tmmtg:5Jffimzg) / 241 11 10 t!lJ/f1tj:iSft,Ji;ii ( NCI CTC AE 4.0 ) / 246 11 11 fFJw
19、.J/tmt1iJj)1J;* / 254 17 -csco *i.RJt I Filif-J Meta 5ttJT, *nlJRtJl3l.tJl.HiJf -ni9. (5z1m 80% ) Filif-J Meta 5ttJT , *llJRtJl3l.HliJt *-ni9. (5zm 60%-80% ) f1f -fiRM_if-J Meta 5ttJT, IJllJRtJlnffll liJt, i9:it Hif-J*)mYil1liJt, m19U -nffllliJt -ni.R (5z1m 80%) f1f -fiRMmif-J Meta 5ttJT, JjlliIllJR
20、tJl3l.tffll liJt, i9:i.t llr if-J * ) mYil1liJt, m19U -n,liJt *-ni9. (5z1m 60%-80% ) 1f Fnffll8Jlrdi*liJt, m19H*, 7Ci9., BiSl.* (5z1m 60%) lIIm# csco itiimm f1(Pf( csco 11Jt1t#$ iF* ,8;llkt1JD 7 Jl!HJ 1 A iIEmiDg 2A iIEmi TJlHP,flifD csco t1J 1A w:tJ,!i, .U,z.*B7t1Z*:J:!oi5UtHfr$DJ&lirEt-.J 2A /GPJ,
21、 t!Jf!.!I!nItw:, Im#o : mW:.,DJ&tl,.fiffim., (-) IZY / T$X A(*.*fi,ImfD.)Et-.Jm 5.3 $1. jf,jTt1JDB: 7, J1 B iIEmiDg 2A iIEm (=) J;t; rucsco t1J 1B w:, &*B7J-fr$ DJ&ttit, i1Z*:J:!oi,RJtEt-.J (=) J;t; Mii2A ijHJ,!i, i1=1J II m#o 1J: It.I$H.iMJlxt,liJfJi:, ttifljJIJw:tJ,!i, iDJ&tj:5l:iMt=1; xtTI*BJl.il
22、l1.iill$8t, *J$J!l,DJ g, -fuDJi1=1J II m# 2B iIEmiD 3 iIEm xtT*.m, .ffimEt-.Jm, M.W:W:ffixt =1, 1Z*m.mDJEt-.J, IIIm# !IDJ&I1.H 2A Ijl 100 5:l fi111 l.lH,.iE , J;iJ;5:lH 1Z*3*i,RJ.U ., tjH)nIJiiEt,l!i, m, m,f,DJ fl(P CSCO 11JIftffi4i:*, 1*$&3gG!Xtimlitfi11J j7;J , ;zjs:(J(11J1iT mT.g!XmmI*_mIffij7;J,
23、 , ;zjs:m1J$m*g/. !XmmI.g!Xm.o *.mIRtt, itfimI :fi/GPJ, t3vf!5!1lnZ-$*o (-) Im /jg$ffij:Jjj 5.3 $:fPJtJJHljlmHtfi ilfri(j:imttf 7, !Jll:ttf 78*JJIJttf 890 (=) JmJmJ$ffiJ.Rjj (=) tJJ*fHjj . 1 itIJi !:1i # WJ i:i:I.-1 1 . IJld:r1P tXl=IjJ(fflI (soft tissue sarcoma, STS) 1ikm*j1;f- rEtl17J3.J(8J-J3.ilE
24、d1:Bpji1l, E!:;fBI. t51XXJ:jj( 1*Jm, th2mJjlEJl1iJfQ-ir1yJYt:l? BJ3t1#FlgJ( 1 10 J3.gJ( mL:E*V;f-9= JIfg, :g 7t*1J)j(Ttfjl7Hm, BI.1EJlJL, BJl:/j, gH1HJ3.J(, rfnlif2Hf,iJtfjlo J3.J(1ik-mJ.t #JYttt,AAWtt,Mtt.tt*,WfQ3o FlJ(r5AJ9fI1pBJ 0.72%1.05% 2. 3J, :;fillIB;cfnj:1!LIKJ9ftlZlll:BJm./ftill, OOmJ 3.5/
25、10 Jj 3J, J+Im);J (4-5) /10 Jj 4 , ftOOm.gJ 2.91110 Jj 5. 6Jo ,*m SEER Jfmit, STS :;f 1ilAff1mBJJo lffOO3J:9:m,f.1!ftl1Ju 1.4 : 1 7, l3.ftOO3J:9:b(:m,f.1!ftl1JUt:ilI 1 : 1 5Jo 1liH1ifij:*, mIljj1W.j:Iilj, *I!I Ilt i5UfEJj-im., 80 * stm.gJj 30 * 8tBJ 8itl 6Jo 4 J3.gJ(:$:1itm BJ Wil:1ik JlHts:, f.J
26、 r5 53%, ;Jt1X1ikJmJj-( 19%), IFF (12%) , *iJIW tt m i,!l, ( 11%) 8Jo J3.gJ(ftmmtq*1J)j(;tH 12 *, N,*m:;ffll%fQ1:!JWJ,:q:Jj, 50 ;ftjl lV.t.ill!. 9Jo :$:1itm.ill!.ID!BI.t5*7tit%I1,*l (undifferentiated pleomorphic sarcoma, UPS), nJl:/jr ( liposarcoma, LPS) :.i:fQ i1f y:$:Itm 8J tXJ3.gJ( Er/ji tXJ3.gJ(
27、Erlisttj: *1wHf:;fBI.t.5 3t 1 GOLDBLUM e-book. Elsevier 2 SIEGEL RL, Ml 3 Surveillance, Ep Nov. 2020 data. 4 CASALI PG, Al Clinical Practic( ment_4): iv268-: 5 YANG Z, ZHH II JVIHdifcp, H/f :=*1)l T r:p llfFz?:, =1fI CJl.t r itll:El:-mpij III ;f!li&lftf$ 0 :i1l:DJ:8tIW$/f:f!l1B1 , JJ; 2.91110 7i 15.
28、 6lo 1:ftWJ!t17UJ $IljjiWJ, tlHJ.liif IR f ( 12%), iff!=1fI 11J;, :;ij 50 ;fjll2JL IE na, UPS !ltJilll ( liposarcoma, LPS ), m!IJL ( leiomyosarcoma, LMS ), mJmr:Ji1I1 (synovial sarcoma, SS) JL li!;fll1iY1flillt.IJt!.Et9ttJ,:Jl.:Ji1I1J;*ja)(!IJL (rhabdomyosarcoma , RMS)o ttJ.:mRjmBf.JWJfJL1ffIJ.&WJ1J
29、J/flljjiiffl, :iffHtE, NFl, Rb E. P53 PJj;.ll1; m :;ij*;&:;ij*m,M&PJnjWJ:f!l*o *tffi*/fi2t5 Jlm:ifti8J W:illi (GIST )o I J GOLDBLUM JR, WEISS SW, FOLPE AL, et al. Enzinger and Weisss Soft tissue tumors e-book. Elsevier Health Sciences, 2013. 2 J SIEGEL RL, MILLER KD, JEMAL A. Cancer statistics, 2020
30、. Ca Cancer Clin, 2020, 70 (I ): 7-30. 3 J Surveillance, Epidemiology, and End Results (SEER) Program (www. seer. cancer. gov). Based on the Nov. 2020 data. 4 J CASALI PG, ABECASSIS N, ARO HT, et al. Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatmen
31、t and follow-up. Ann Oncol, 20 18, 29 (Supplement_ 4): iv268-269. 5 J YANG Z, ZHENG R, ZHANG S, et al. Incidence, distribution of histological subtypes and primary sites of soft tissue sarcoma in China. Cancer Bioi Med, 2019, 16 (3): 565-574. 6 BURNINGHAN Z, HASHIBE M, SPECTOR L, et al. The epidemio
32、logy of sarcoma. Clinical Sarcoma Research. BioMed Central, 2012, 2 (1): 14. 7 J FERRARI A, SULTAN T, HUANG TT, et al. Soft tissue sarcoma across the age spectrum: a population-based study from the Surveillance Epidemiology and End Results database. Pediatr Blood Cancer, 2011 , 57 (6): 943-949. 8 J
33、MEHREN VON M, RANDALL RL, BENJAMIN RS, et al. Soft Tissue Sarcoma, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. Natl Compr Canc Netw, 2018,16 (5): 536563. 19 J WHO Classification of Tumours Editorial Board. Soft Tissue and Bone Tumours: WHO Classification of Tumours 5th Edition. Wo
34、rld Health Organization, April 24, 2020. 1.2 EI?&l l!lJ Jlt mmil:7-J5*X.tt*, =.tt,mfiM, il5Tt: *)E:ift:f$JillE!t , tI:ljj1-1L *, t!:!l3i:1*7.K.p 1.3 1, EIJ1Ei!t#/f;fftif*tto ;ffmill 1lrlJl2JtI:lI.mJJ.p*mJlrJpqmJI!1* , &:AAiffiU3t*, IRfE#fEti.p* , wlH.pillUJIJ7tiJPT 4. ilffi *f.m.!:tEfjJ3tffi;k , ,*l
35、1fjJ3tj.llj sJPf1.m:7-Jmfi1lHIL 1f!. H :I I.mJill:fTWft&rlffJ510 tii;(:tif, l 68 10 *xtEl; ill,m:lf1:; fttll3lI1J1:mlJ 0 /G -=F 9t;1JlX:I!f rjJJm rtJ)i /t(t, :nq.Jnff ll./t( il * i &:kTr*x 1910 PI RJ*o MIJ1l!1m./t(jji J1i 5!e iJ fiIT$1V *Xlj/t( Jfil-g, sJ $1I, :*:/), ll.f($:; ;ff/G Jt7t sJ)if4JtI l2
36、J &: Jl9c *m1ltvtFrf 64% 13 1; rjJil*/JY ;fn 33% 114 1MSTS (0 90% , 81%;fn56% 1. 15 . 7t;)Ij:7-J 85.3%, 83.0% coma. Clin ical Sarcoma 1ge spectrum: a populaase. Pediatr Blood Can-me Sarcoma, Version letw, 2018,16 (S): S36L1rs: WHO Classification 3 if, nifa1iWr GJl.:fHifjftL :ffWJ IftJlJ Bi fa1i JJU3
37、+BJpJ t :fJl1fll1l:H$1Zi1fiJ5 ;ljtr, 6-S ,0 mfa1i.fi,*, ili., jt8,.BJ_ 8ifll1iInrIJ 0 -*1I1B91fa1i BJ WJ1io -*3:$t&;fIlFitllIJf* , ft!.t m .:l;f, ni fa1irJ 6Hf * , JIfEltllLMI, tJlZni mI J1M.Jffi:ff:ill W-, 1it11 jf!lBi fa1i Ill Jffilil .e, .;ljt*;fIl8*0 XilJ( Ifa1i*:clf!jltp3WBJftm3:J1Jli8%, *-Ti!/
38、li , ML trpJm, iW* , 1f lZ*-Ti*X1f 9Jo 1fll:ibBJim;YUMlJjljil:fffgBtBJmftffl , rl&:mt1J, *-Ti , qgEltilBirl7i BJ*o fa1imrllli,.;fIl.*.:l;fmoo*,tttt fa1i9JBJffij$1j0 mfa1iBJs*6omfa1iMJ5BJ3:.:ffif., fa1i $1iL */J, JHJ(:5H1L tE8EU:H$1iI lo . 11 Jo lI(rimJ fa1iffij$;ljtB.3: :ff/GJt:5J-BJ6f4:illW-, $j(;l
39、jt, Bifa1i1-*fR*, JH);:5t 12 Jo xilJ(rl7i:5tWL* kJ.&I!9c*mMJ5, 1JO: m:f!Il:5t 1 , 2 ;fIl 3 BJ7C_.*:5tjJU98%, 8S% 5f11 64% 13 l; Bifa1i*/J IScm, ;!J,: S *:5tjJIJ 84%, 70%, SO% ;fIl33% 14 Jo MSTS (Musculoskeletal Tumor Society) :5tWJ I WJ, II WJ5f11illWJiJ S ,g&*:5tjJIJ j;J 90%, 81%;fIl S6% r15 JAlCC:
40、5tWJ I A WJ, I B WJ, II WJ, ill AWJ, illB WJ,filNWl BJ S if,g,*o :5tjJU8S.3%, 83.0%, 79.0%, 62.4%, SO.I%, 13.9%16lo ysis of patterns OJ 9 J ENNEKING WE l: 10 J ATEAN I, pon 1 J COLLIN C, GODBOLD J, HAJDU S, et al. Localized extremity soft tissue sarcoma: an analysis of adults. A single factors affec
41、ting survival. J Clin Oncol, 1987, 5 (4): 601-612. 11 J JZ!;, L:j:S%m 2 J RUSSELL WO, COHEN J, ENZINGER F, et al. A clinical and pathological staging system for soft tis;il; , 2011, 49 (1 sue sarcomas. Cancer, 1977,40 (4): 1562-1570. 12 J PISTERS PW, 3 J GOLDBLUM JR, WEISS SW, FOLPE AL, et al. Enzin
42、ger and Weisss soft tissue tumors e-book. Elsewith localized s vier Health Sciences, 2013. 13 J ZAGARS GK, 4 J RIAD S, GRIFFIN AM, LIBERMAN B, et al. Lymph node metastasis in soft tissue sarcoma in an soft-tissue sarc extremity. Clin Orthop Relat Res, 2004, 426: 129-134. patients. Cancel 5 1 BEHRANW
43、ALA KA, AHERN R, OMAR AM, et al. Prognosis of lymph node metastasis in soft tis 14 J RAMANATHA gg sue sarcoma. Ann Surg Oncol, 2004, 11 (7): 714-719. tissue sarcomas 6 J GARCA FRANCO CE, ALGARRA SM, EZCURRA AT, et al. Long-term results after resection for 15 J EDGE SB, COl T soft tissue sarcoma pulm
44、onary metastases. Interact Cardiovasc Thorac Surg, 2009, 9 (2): 223-226. cancer staging I$j: !:Il l:R 7 J GADD MA, CASPER ES, WOODRUFF JM, et al. Development and treatment of pulmonary metasta 16 J FISHER SB, C iij ses in adult patients with extremity soft tissue sarcoma. Ann Sur, 1993, 2 18 (6): 70
45、5-712. the American J 8 BILLINGSLEY KG, BURT ME, JARA E, et aI. Pulmonary metastases from soft tissue sarcoma: anal-extremities. Aru 11 :arcoma: an analysis of ging system for soft tis-LIe tumors e-book. Elseft ti ssue sarcoma in an e metastasis in soft tis:ults after resection for )9,9 (2): 223-226
46、. of pulmonary metasta705-712. ,ft tissue sarcoma: analysis ofpattems of diseases and postmetastasis survival. Ann Surg, 1999,229 (5): 602-612. 9 J ENNEKING WF, et al. Musculoskeletal tumor surgery. Churchill Livingstone, 1983. 10 J ATEAN I, POINTREAU Y, ROSSET P, et al. Prognostic factors of extrem
47、ity soft tissue sarcoma in adults. A single institutional analysis. Cancer Radiother, 20 12, 16 (8): 661-666. II J *jlg , t:j=. Hit: M , iHJ * . )JjC:1li Hx til tp iJ;J 208 JtlTE BJ i rz;J 5Hfr . !=f:$ 7*4 , 2011, 49 (II): 964-969. 12 J PISTERS PW, LEUNG DH, WOODRUFF J, et al. Analysis of prognostic
48、 factors in 1,041 patients with localized soft tissue sarcomas of the extremities. J Clin Oncol, 1996, 14 (5): 1679-1689. 13 J ZAGARS GK, BALLO MT, PISTERS PWT, et al. Prognostic factors for patients with localized soft-tissue sarcoma treated with conservation surgery and radiation therapy: an analy
49、sis of 1225 patients. Cancer, 2003, 97 (10): 2530-2543 . 14 J RAMANATHAN RC, FISHER C, THOMAS JM, et al. Modified staging system for extremity soft tissue sarcomas. Ann Surg Oncol, 1999,6 (I): 57-69. 15 J EDGE SB, COMPTON Cc. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer
50、 staging manual and the future ofTNM. Ann Surg Oncol, 2010, 17 (6): 1471-1474. 16 J FISHER SB, CHIANG YJ, FEIG BW, et al. Comparative performance of the 7th and 8th Editions of the American Joint Committee on Cancer Staging Systems for soft tissue sarcoma of the trunk and extremities. Ann Surg Oncol
